Uploaded September 2024 | Updated November 2026, 3 hours ago
In “I have MOGAD. Now what?” the first episode of the “ABCs of MOGAD” series, Krissy Dilger of SRNA was joined by Dr. Michael Levy. Dr. Levy explained the MOG antibody disease diagnosis, including its autoimmune nature and symptoms [00:01:12]. The discussion covered the history and evolution of the disorder, distinguishing it from other disorders like multiple sclerosis and neuromyelitis optica [00:05:24]. Dr. Levy detailed the diagnostic process, including antibody tests, MRIs, and clinical criteria [00:13:47]. The episode also explored treatment options, long-term effects, and the prognosis of the disease [00:29:30].
Michael Levy, MD, PhD is an Associate Professor of Neurology at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology & Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine with a focus on neuroscience. In 2009, Dr. Levy was appointed to the faculty as Assistant Professor at Johns Hopkins where he started the Neuromyelitis Optica Clinic and Research Laboratory and in 2019 he moved to the Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
Clinically, Dr. Levy specializes in taking care of patients with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease, acute disseminated encephalomyelitis and optic neuritis. In addition to neuroimmunology clinics, Dr. Levy has a special interest in patients with superficial siderosis of the central nervous system. Dr. Levy is the principal investigator on several clinical studies and drug trials for all of these conditions.
In the laboratory, Dr. Levy’s research focuses on the development of animal models of neuromyelitis optica and transverse myelitis with the goal of tolerization as a sustainable long-term treatment.
00:00 Introduction and Guest Introduction
01:33 Understanding MOG Antibody Disease
03:09 History and Discovery of MOG Antibody Disease
06:13 Diagnostic Process for MOG Antibody Disease
09:09 Acute and Long-Term Treatment Options
14:33 Choosing the Right Treatment
16:01 Rehabilitation and Follow-Up
18:42 Long-Term Effects and Prognosis
22:19 Conclusion and Future Discussions
In “I have MOGAD. Now what?” the first episode of the “ABCs of MOGAD” series, Krissy Dilger of SRNA was joined by Dr. Michael Levy. Dr. Levy explained the MOG antibody disease diagnosis, including its autoimmune nature and symptoms [00:01:12]. The discussion covered the history and evolution of the disorder, distinguishing it from other disorders like multiple sclerosis and neuromyelitis optica [00:05:24]. Dr. Levy detailed the diagnostic process, including antibody tests, MRIs, and clinical criteria [00:13:47]. The episode also explored treatment options, long-term effects, and the prognosis of the disease [00:29:30].
Michael Levy, MD, PhD is an Associate Professor of Neurology at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology & Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine with a focus on neuroscience. In 2009, Dr. Levy was appointed to the faculty as Assistant Professor at Johns Hopkins where he started the Neuromyelitis Optica Clinic and Research Laboratory and in 2019 he moved to the Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
Clinically, Dr. Levy specializes in taking care of patients with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease, acute disseminated encephalomyelitis and optic neuritis. In addition to neuroimmunology clinics, Dr. Levy has a special interest in patients with superficial siderosis of the central nervous system. Dr. Levy is the principal investigator on several clinical studies and drug trials for all of these conditions.
In the laboratory, Dr. Levy’s research focuses on the development of animal models of neuromyelitis optica and transverse myelitis with the goal of tolerization as a sustainable long-term treatment.
00:00 Introduction and Guest Introduction
01:33 Understanding MOG Antibody Disease
03:09 History and Discovery of MOG Antibody Disease
06:13 Diagnostic Process for MOG Antibody Disease
09:09 Acute and Long-Term Treatment Options
14:33 Choosing the Right Treatment
16:01 Rehabilitation and Follow-Up
18:42 Long-Term Effects and Prognosis
22:19 Conclusion and Future Discussions

![2026 RNDS | Novel Methods for the Discovery of Disease-Associated T Cell Epitopes in Autoimmunity
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Barbara Willekens, MD, PhD, of Antwerp University Hospital and the University of Antwerp, presenting remotely, spoke about how scientists look for the targets that T cells attack in autoimmunity [00:00:05]. She described what T cells do and what is known about their targets in aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody disease (MOGAD) [00:00:40]. She explained epitopes, peptides and immune display molecules, and why T cell targets are much harder to find than antibodies [00:04:05]. Dr. Willekens reviewed newer research tools, including methods that read the molecules presenting protein pieces, ELISpot, and single T cell analysis [00:08:52]. She closed with what this work could mean for diagnosis, monitoring and more precise treatments, and answered an audience question about the path toward a cure [00:13:15].
Barbara Willekens, MD, PhD, is a neurologist at Antwerp University Hospital (UZA) and a part-time professor at the University of Antwerp, appointed in 2023. She studied medicine at the University of Antwerp, trained as a neurologist in Antwerp and Utrecht, and joined UZA in 2007 to build up clinical and research work on multiple sclerosis. Her research focuses on inflammatory diseases of the central nervous system, including cell immunotherapy and biomarkers, with main areas of multiple sclerosis, MOGAD, NMOSD, autoimmune encephalitis and Susac syndrome. She is chief investigator of the MACSiMiSE-BRAIN trial of metformin in progressive MS.
00:00 Finding the Target of the Immune System
00:40 What T Cells Do
01:54 T Cell Targets in NMOSD and MOGAD
04:05 Epitopes and Peptides Explained
05:05 Why T Cells Are Hard to Find
07:53 Three Families of Methods
08:52 Newer Research Tools
10:29 ELISpot
12:15 Single Cell Analysis
13:15 Why This Matters
15:25 Audience Question
17:03 Closing Thanks 2026 RNDS | Novel Methods for the Discovery of Disease-Associated T Cell Epitopes in Autoimmunity](https://i.ytimg.com/vi/RyHEm7TtRBQ/mqdefault.jpg)


![102. Dr. Paula Barreras
The Community Meets Clinic podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode, Krissy Dilger of SRNA was joined by Dr. Paula Barreras. Dr. Barreras discussed her journey into neuroimmunology, emphasizing the impact of patient interactions [00:01:31]. Her early research focused on misdiagnoses in disorders like transverse myelitis, later expanding to neurosarcoidosis, aiming to improve diagnostic accuracy [00:02:42]. She shared how Cedars-Sinais multidisciplinary clinic, enhanced by specialists, offers comprehensive care, aiming to address patients various needs efficiently [00:05:41]. You can view the medical profile of Dr. Barreras here:
https://www.cedars-sinai.org/provider/paula-barrerascortes-4003480.html#fad-provider-bio featured
Dr. Paula Barreras is a board-certified neurologist with expertise in neuroimmunology. She is an assistant professor of neurology at Cedars-Sinai Medical Center in Los Angeles. Dr. Barreras specializes in immune mediated conditions affecting the brain and spinal cord, including neurosarcoidosis and spinal cord disorders such as neuromyelitis optica, MOG associated disease, transverse myelitis, and their mimics.
Dr. Barreras completed her medical school at the University of the Andes, followed by a postdoctoral research fellowship in neuroimmunology at Johns Hopkins University. She completed her neurology residency and clinical neuroimmunology fellowship also at Johns Hopkins before joining the team at Cedars-Sinai Medical Center. Her research focuses on identifying predictors of final diagnosis after the initial diagnosis of myelopathy, as well as predictors of outcomes in myelitis and neurosarcoidosis. 102. Dr. Paula Barreras](https://i.ytimg.com/vi/STrcnYrR_4Q/mqdefault.jpg)


![Ask the Expert 1411. All About the Rare Neuroimmune Disorders Symposium
In this SRNA “Ask the Expert” episode, Krissy Dilger of SRNA introduced the Rare Neuroimmune Disorder Symposium (RNDS), a three-day hybrid event in Dallas, Texas (October 15–17, 2026) that connects individuals and families with leading experts for education on diagnosis, symptom management, rehabilitation, mental health, and research. You can view details about RNDS, including the agenda and registration, on the event page:
https://www.srna.ngo/2026-rnds
SRNA founder and president Sandy Siegel recounted how early community isolation and a 1999 gathering helped spark ongoing symposia [00:08:37]. He described the development of a medical advisory board and collaboration with Johns Hopkins that supported research growth, evolving diagnostic definitions, and advances such as plasma exchange and newer therapies for conditions including TM, NMOSD, ON, ADEM, AFM, and MOGAD [00:12:11]. Community support coordinator Leah Campbell shared about her neuromyelitis optica (NMO) diagnosis and described RNDS as invaluable for expert access, treatment decision support, and meaningful connection with others who share similar experiences [00:34:45].
Sandy Siegel is the President of SRNA. Sandy got involved with SRNA shortly after his wife, Pauline, contracted TM in 1994 at the age of 35. At the time of her onset, Pauline was a kindergarten teacher. Sandy has been an officer and a board member of SRNA since its inception. Sandy has also served as SRNA’s newsletter and journal editor during his more than two decades of service to the organization. Sandy is a cultural anthropologist with specializations in Native Americans, psychological anthropology, and culture change. Sandy has worked as an adjunct professor at Capital University, Franklin University, the Urban/Rural Program of the College of Great Falls, and the Intertribal Education Center of the Fort Belknap Reservation. Sandy retired from the State of Ohio in 2011 after more than 35 years of service. Sandy returned to college in the fall of 2011 as a photography student at Columbus State Community College. Sandy and Pauline have two sons, four grandsons, and one granddaughter.
Leah Campbell is SRNAs Community Support Coordinator. Leah was diagnosed with neuromyelitis optica (NMO) in May 2006 after 17 years of unexplained symptoms and misdiagnosis. She was the first blind student and salutatorian of Altus High School and the first blind graduate of Rhodes College, earning a BA in mathematics. Following graduation and after a treatment for a disease she had been misdiagnosed with, she became quadriplegic and lost sensation of touch, having to relearn how to navigate life as both blind and paralyzed. She is dedicated to using her experiences to support and advocate for others.
00:00 Welcome
01:03 What the Rare Neuroimmune Disorders Symposium Offers
02:35 Meet Sandy and Leah
03:13 Origins of RNDS
08:37 1999 Breakthrough Symposium
12:11 Centers of Excellence Growth
22:31 How RNDS Evolved
31:30 Why RNDS Still Matters
34:45 Leahs Journey with NMOSD
35:43 Leahs RNDS Experience
38:40 Advice and Closing Ask the Expert 1411. All About the Rare Neuroimmune Disorders Symposium](https://i.ytimg.com/vi/TW04wCPKhSE/mqdefault.jpg)

![2026 RNDS | Diagnostic Workup Masterclass: Medical Professionals Share Insight on Tests and Criteria
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Benjamin Greenberg, MD, MHS, of the University of Texas Southwestern, Carlos A. Pardo, MD, of Johns Hopkins University, and Shuvro Roy, MD, of the University of Washington discussed how diagnosis of rare neuroimmune disorders has changed over 25 years [00:01:25]. Dr. Pardo described how registries and stored blood and spinal fluid samples led to the discovery of the aquaporin-4 and MOG antibodies, and why listening to the person in front of you still matters [00:02:49]. Dr. Greenberg explained how clinicians learn to recognize new conditions, using acute flaccid myelitis as an example, and Dr. Roy described how understanding of MOG antibody disease (MOGAD) has evolved, including the 2023 diagnostic criteria and the gray areas that remain [00:08:39]. The panel explained why antibody tests differ between labs, why timing and levels matter, and why a test result is not a diagnosis by itself [00:15:50]. They also cautioned about direct-to-consumer testing panels [00:25:57].
Benjamin Greenberg, MD, MHS, directs the Transverse Myelitis and Neuromyelitis Optica Program at the University of Texas Southwestern Medical Center and is recognized internationally as an expert in rare autoimmune disorders of the central nervous system. His research focuses on better ways to diagnose and treat these disorders, including biomarkers that may help distinguish between neurologic conditions.
Carlos A. Pardo, MD, is a Professor of Neurology and Pathology in the Division of Neuroimmunology and Neuroinfectious Disorders at Johns Hopkins University School of Medicine and Director of the Johns Hopkins Myelitis and Myelopathy Center in Baltimore, Maryland. He is the principal investigator of the Neuroimmunopathology Laboratory and a clinical neurologist at the Multiple Sclerosis and Transverse Myelitis Centers at Johns Hopkins Hospital. His clinical specialization is neuroimmunological and infectious disorders of the nervous system, with particular focus on multiple sclerosis, transverse myelitis, neurosarcoidosis, and neurological complications of autoimmune disorders.
Shuvro Roy, MD, is an Assistant Professor of Neurology at the University of Washington, specializing in neuroimmunology, with a focus on multiple sclerosis and related neuroimmunologic disorders. He is Co-Director of the UW SRNA Center of Excellence for Rare Neuroimmune Disorders. Dr. Roy is engaged in projects aimed at improving access to care, addressing healthcare disparities, and enhancing patient safety for people living with MS and related conditions.
00:00 Welcome and Introductions
01:25 How Diagnosis Has Changed
02:49 Registries, Samples and Listening
08:39 Recognizing New Conditions
11:26 Learning About MOGAD
15:50 Why Antibody Tests Differ
21:14 A Test Result Is Not a Diagnosis
25:57 Direct-to-Consumer Testing
29:45 Putting the Pieces Together 2026 RNDS | Diagnostic Workup Masterclass: Medical Professionals Share Insight on Tests and Criteria](https://i.ytimg.com/vi/U-eV0oRo3Jc/mqdefault.jpg)
![2024 RNDS | What’s my Diagnosis? Community Members Share their Diagnostic Journey
At the 2024 RNDS, Dr. GG deFiebre of the Siegel Rare Neuroimmune Association (SRNA) spoke with community members, Angela Jackson, Andrew Jopson, Ashley Harrington, Lyd Lacey and Andreas Melitsanopoulos about their diagnostic journey. The participants shared their diagnostic journeys and the onset of their symptoms [00:00:30]. The conclusion revealed the specific diagnoses of each participant and emphasized the similarities and differences in their experiences [00:35:55].
00:00 Introduction and Panel Overview
00:37 Panelist Introductions
01:29 Initial Symptom Onset
07:39 Detailed Symptom Experiences
21:49 Diagnostic Tests and Challenges
27:22 Initial Treatments and Responses
30:24 Personal Reflections and Support
35:55 Revealing the Diagnoses
37:36 Conclusion and Organizational Impact 2024 RNDS | What’s my Diagnosis? Community Members Share their Diagnostic Journey](https://i.ytimg.com/vi/U4awgJE6lxo/mqdefault.jpg)